Lead analyst says ” Global Biosimilars and Follow-on Biologics Drugs market set to grow to $29bn by 2023″

18 June 2018
Pharma

Visiongain’ has launched a new pharma report Global Biosimilars and Follow-On Biologics Market : Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones

A biosimilar is a biological drug that is ‘highly’ similar to an already approved branded biologic. Patents on many leading biologic products are set to expire in the coming years, opening them up to biosimilar competition and offering hope to patients and nations alike. The market is set to experience rapid growth between 2016 and 2028, with many pharmaceutical companies developing biosimilars to take advantage of that market’s vast potential and patients’ needs. Biosimilars are already well-established in emerging markets, however developed markets have traditionally lagged behind.

The lead analyst of the report commented “The US is not the only country that will drive growth in the global biosimilars market. Other developed markets, such as those in Europe, present an opportunity for growth. Many of these nations face huge deficits in their national healthcare budgets and are in need of the huge savings that biosimilars can provide. This is especially true given the rising prevalence of chronic diseases which are placing a huge strain on national healthcare budgets.

Emerging markets have traditionally posed the best opportunity for growth for biosimilars, and they will continue to be a source of growth throughout the forecast period. These nations have limited budgets, combined with large ageing populations, which presents a need for biosimilar therapies. Biosimilars offer these nations a way to widen access to healthcare at a reasonable cost.”

Leading companies featured in the report include Sandoz, Teva, Hospira, Celltrion, Amgen, Dr. Reddy’s Laboratories, 3SBio, Wockhardt , Ranbaxy, LG Life Sciences, Biocad, Boehringer Ingelheim, PROBIOMED

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Liposomal Drug Delivery Devices Market Report 2022-2032

Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.

21 June 2022

Read

Visiongain Publishes Nanotechnology in Drug Delivery Market Report 2022-2032

The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.

20 June 2022

Read

Visiongain Publishes Respiratory Drug Delivery Technologies Market Report 2022-2032

The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.

15 June 2022

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2022-2032

The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.

14 June 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever